Holen Sie sich die Stockscreener-App
0.7811
2.03%
-0.0161
Schlusskurs vom Vortag:
$0.7972
Offen:
$0.7889
24-Stunden-Volumen:
64,736
Relative Volume:
0.21
Marktkapitalisierung:
$37.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-77.90M
KGV:
-0.4843
EPS:
-1.6127
Netto-Cashflow:
$-30.38M
1W Leistung:
-8.93%
1M Leistung:
-21.51%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.7581
$0.8097
1-Wochen-Bereich:
$0.75
$0.8939
52-Wochen-Spanne:
$0.75
$2.0901
Filana Therapeutics Inc Stock (FLNA) Company Profile
Firmenname
Filana Therapeutics Inc
Sektor
Branche
Telefon
512-501-2444
Adresse
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN
Compare FLNA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FLNA
Filana Therapeutics Inc
|
0.7811 | 38.51M | 0 | -77.90M | -30.38M | -1.6127 |
VRTX
Vertex Pharmaceuticals Inc
|
521.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.21 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.49 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.88 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Filana Therapeutics Inc Stock (FLNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-27 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-01-10 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Filana Therapeutics Inc Aktie (FLNA) Neueste Nachrichten
Filana (FLNA) Latest Quarter: EPS Clears the Reported Estimate in the Latest Reading; Post-Report: Shares Close 3.23% Lower in Latest TradingEarnings Miss Streak - vinanet.vn
Filana (FLNA) Earnings Snapshot: The EPS Result Is Above Expectation in Latest Trading; After Results: The Market Price Declines 3.72% for the Current SessionMargin Compression Risk - vinanet.vn
Filana Therapeutics, Inc. (NASDAQ: FLNA) Share Price, FLNA Stock News, FLNA Share Price & Updates - Kalkine
Filana Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | PX91 | US14817C1071 - marketscreener.com
Cassava Sciences Securities Litigation Ruling: Court Denies Ugarte Dismissal Motions Without Prejudice While Awaiting Fifth Circuit Ruling - TipRanks
Law firm investigates Filana Therapeutics officers for possible shareholder rights breaches - Pluang
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
FLNA Q3 2025 Earnings: Narrower Loss Beats Estimates by 20.12% as Shares Dip 2.58%Earnings Manipulation Risk - vinanet.vn
FLNA Q3 2025 Earnings: Narrower Loss Beats Estimates; Stock Gains 0.2%Peak Earnings Alert - vinanet.vn
Filana Therapeutics (FLNA) Climbs 3.75% as Micro-Cap Biotech Approaches Key Resistance at $1.04Volatility Smile - dars.gov.et
Filana Therapeutics (FLNA) Slides 3.3% to $1.00 as Small-Cap Biotech Approaches Key SupportEarnings Miss Risk - dars.gov.et
Weekly Recap: FDA clinical hold on TSC trial and Q2 2026 cash $82.7M - TradingView
FLNA Q3 2025 Earnings: Narrower-than-Expected Loss Lifts Shares 5.21%Negative Surprise Momentum - vinanet.vn
Maxim Group Maintains Filana Therapeutics(FLNA.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update - GlobeNewswire
Filana Therapeutics Q2 EPS beats estimate, loss narrows 81% - scanx.trade
Filana Therapeutics Faces Pressure as Shares Slide 4.43%Support at $0.85 in FocusIV Spike - vinanet.vn
Filana Therapeutics, Inc. Revenue Breakdown – NASDAQ:FLNA - TradingView
Filana Therapeutics (FLNA) AGM 2026 Summary - Quartr
Filana Therapeutics (FLNA) Q4 2025 earnings summary - Quartr
Filana Therapeutics (FLNA) Slides 5% as Bearish Momentum Builds; Key Support at $1.04 in FocusATR Stop - dars.gov.et
MSN Money - MSN
FLNA Price Today: Filana Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Despite Stock SlideEPS Surprise History - dars.gov.et
Filana Therapeutics (FLNA) Surges 4.8% as Biotech Momentum BuildsUpthrust Pattern - dars.gov.et
FLNAFilana Therapeutics Inc Short Interest - Finviz
FLNA Should I Buy - Intellectia AI
Price to sales forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Price to book forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Filana Therapeutics, Inc. Actuals & Estimates (NASDAQ:FLNA) - TradingView
Filana Therapeutics, Inc. Actuals & Estimates (TRADEGATE:PX91) - TradingView
Enterprise value to revenue forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Price to earnings forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
FLNA Forecast — Price Target — Prediction for 2027 - TradingView
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
Filana Therapeutics (FLNA) Holds Near Support Amid Modest DeclinePrice Surge Stocks - dars.gov.et
Filana Therapeutics Shareholders Back Board, Compensation Plans - The Globe and Mail
FLNA Q3 2025 Earnings: Narrower Loss Beats Street, But Shares Slide on UncertaintyLow Estimate Range - newsline.com
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Trend Analysis - newsline.com
Filana Therapeutics, Inc. 8-K Filing Details: Amended 2018 Omnibus Incentive Plan and Company Information (June 2026) – Minichart - Minichart
Filana Therapeutics (FLNA) investors back directors, plan changes and auditor - Stock Titan
Filana Therapeutics (FLNA) Slips 4.6% as Biotech Sector Headwinds Test SupportConversion Trade - newsline.com
FLNA: All proposals passed as the company focuses on resolving the FDA clinical hold for its TSC program - TradingView
Filana Therapeutics (FLNA) Surges Over 8%—Testing Key Resistance at $1.50Beta Neutral Pair - newsline.com
Filana Therapeutics (FLNA) Edges Higher as Stock Tests Key Resistance LevelTrend Following Picks - newsline.com
Filana Therapeutics (FLNA) Slips 4.5% as Stock Approaches Key Support LevelIV Rank - newsline.com
Data I/O And 2 Other Promising Penny Stocks To Watch - simplywall.st
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Stock RallyEarnings Surprise Stocks - The Legal Advocate
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Propels Shares HigherEarnings Volatility Report - dars.gov.et
Finanzdaten der Filana Therapeutics Inc-Aktie (FLNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):